Chiyeso chachipatala chovomerezedwa ndi FDA cha khansa ya muubongo ya glioblastoma

Kairos Pharma, Ltd., kampani yomwe ili mwachinsinsi pazachipatala yomwe imayang'ana kwambiri kukana mankhwala ndi immunotherapy pa khansa, lero yalengeza kuti T cell therapy yake, KROS 201, yalandila chilolezo cha FDA kuti apitilize kuyesa kwachipatala kwa Phase 1 kwa odwala omwe akubwereza. glioblastoma, mtundu wa khansa ya muubongo. Mlandu wa gawo I umathandizidwa ndi Kairos Pharma ndipo udzachitikira ku Cedars Sinai Medical Center ku Los Angeles.

Mtsogoleri wamkulu wa Kairos John Yu, MD adati, "Kuvomereza kwa IND ndi gawo lachiwiri lachipatala mkati mwa mwezi wapitawu pamene Kairos akufulumizitsa kukwaniritsa zolinga zake zachipatala za 2022. maselo pamizu ya glioblastoma."

Kairos Chief Scientific Officer Neil Bhowmick, Ph.D. Anawonjezera kuti, "Kupambana kumeneku kumakankhira envelopu yamankhwala oteteza chitetezo chamthupi omwe amapangidwa kuti ayang'ane ma T cell motsutsana ndi khansa yowononga."

KROS 201 activated T cell (ATCs) ndi maselo akupha T omwe amapangidwa mu chikhalidwe cha cell poyambitsa maselo oyera amagazi a odwala omwe ali ndi ma cytokines kapena ma T cell activating sign komanso ma priming dendritic cell odzaza ndi ma antigen enieni a khansa ya glioblastoma. Ma cell amphamvu a T amalowetsedwa m'mitsempha mwa odwala omwe ali ndi glioblastoma yobwereza. Maselo amenewa awonetsedwa kuti amapha maselo a khansa, omwe amayambitsa khansa.

Kuphatikiza pa kuyesa kwa Gawo 1 komwe kukubwera kwa T cell therapy ya KROS 201, kuyesa kwa Phase 2 kwa ENV105 ndi apalutamide posachedwapa kunapatsidwa IND ndi FDA mu February. Mayesero a Phase 1 a ENV105 ndi Tagrisso (AstraZeneca) a khansa ya m'mapapo akuyembekezeka kuyamba mu 2022.

Pamodzi ndi kupita patsogolo kwa zochitika zake zachipatala, Kairos Pharma adalengeza chilolezo cha Ofesi ya United States Patent ndi Trademark ya Mapangidwe awo a Patent ndi Njira Zochizira Fibrosis. Patent iyi imakhudza njira yochizira fibrosis ndi mitundu ina ya khansa, kapangidwe kake, komanso kupereka chithandizo pogwiritsa ntchito KROS-401, cyclic peptide inhibitor ya IL-4 ndi IL-13 cytokine receptor complex. Mankhwalawa awonetsedwa kuti amachiza fibrosis ndi khansa posintha kusintha kwa M1 kupita ku M2 immunosuppressive macrophage mu khansa zonse ndi fibrosis.

Dr. John Yu, mkulu wa kampani ya Kairos Pharma adati, "Chochitika ichi chikuthandiziranso kale komanso luso lazachuma la Kairos ndipo zimathandizira kuti bukuli liziyenda bwino komanso zochiritsira zosinthika."

Kairos VP of Research and Development Dr. Ramachandran Murali, yemwe anayambitsa molekyulu ya KROS 401, anati, "KROS-401, kuwonjezera pa fibrosis ndi khansa, imatsegula njira yatsopano yochizira matenda a ubongo monga matenda a Alzheimer's."